"rationale","uuid:ID","id","versionIdentifier","studyAcronym","studyTitle"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","a13bcfe5-09d6-497a-9ac8-755406b888e6","StudyVersion_1","2","LZZT","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease"
